Nobiletin alleviates endometriosis via down-regulating NF-κB activity in endometriosis mouse model

Nobiletin exhibits protective potential on inflammation and inhibits the activation of transcription factors nuclear factor-kappa B (NF-kappa B). However, its effects on the progression of endometriosis remain unsettled. The present study aimed to explore the in vivo alleviation of nobiletin on endometriosis and its mechanism of action. The mouse model of endometriosis was established and administered with nobiletin. The ectopic lesion size was measured and the hotplate test was performed to assess the amelioration of nobiletin on endometriosis. The expression of proliferation and angiogenesis relevant genes including proliferating cell nuclear antigen (PCNA), vascular endothelial growth factor (VEGF), and E-cadherin was measured by immunostaining and the mRNA expression of proinflammatory mediators including interleukin (IL)-6, IL-1 beta, tumor necrosis factor (TNF)-alpha, matrix metalloproteinases (MMP)-1, and MMP-3 was measured by RT-PCR. The change of NF-kappa B activity in endometriotic cells was evaluated by Western blotting and confirmed by luciferase assay. Administration of nobiletin significantly reduced lesions size and pain in endometriosis mice. Nobiletin significantly altered the expression of PCNA, VEGF, and E-cadherin in ectopic endometrium, as well as the levels of IL-6, IL-1 beta, TNF-alpha, MMP-1, and MMP-3. Nobiletin also showed remarkably impairment on the activation of NF-kappa B in promoting endometriotic cells, likely targeting on the activity of I.B kinases (IKKs). The present study provides the first evidence that nobiletin exerts protection on endometriosis via inhibition the activation of NF-kappa B, specifically on the activity of I kappa B kinases.